Science Committee

The Science Committee evaluates new scientific evidence about asthma care, and prepares updates to scientific reports on asthma management and prevention.

 

Helen K. Reddel, MBBS, PhD, Chair
Woolcock Institute of Medical Research
PO Box M77 Missenden Road
Camperdown, NSW 2050, Australia

Len Bacharier, MD
St. Louis Children's Hospital
Division of Allergy & Pulmonary Med
One Children's Place
St. Louis, MO 63110

Eric D. Bateman, MD
University Cape Town Lung Institute
George Street, Mowbray, 7700
Cape Town, South Africa.

Louis-Philippe Boulet MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec
2725 Chemin Sainte-Foy
Quebec (QC) G1V 4G5
Canada

Guy Brusselle, MD, PhD, FERS
Department of Respiratory Medicine
Ghent University Hospital
B-9000 Ghent, Belgium

Dr. Roland Buhl
III. Medizinische Klinik
Universitätsklinik Mainz
D 55101 Mainz, Germany

Mark FitzGerald, MD
UBC Respiratory Medicine
Vancouver General Hospital
2775 Laurel Street, 7th Floor
Vancouver, BC V5Z 1M9 CANADA

Louise Fleming, MD
Department of Respiratory Paediatrics
Royal Brompton Hospital
Sydney Street, London

Hiromasa Inoue, MD
Department of Pulmonary Medicine
Graduate School of Medical and Dental Sciences Kagoshima University
8-35-1 Sakuragaoka
Kagoshima 890-8520, Japan

Jerry A. Krishnan, MD, PhD
Division of Pulmonary, Critical Care, Sleep, and Allergy
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 60612

Soren Erik Pedersen, MD
Department of Pediatrics
Kolding Hospital, Shovvangen 2 8
DK 6000, Kolding DENMARK

Aziz Sheikh, MD
Professor of Primary Care Research & Development
Usher Institute of Population Health Sciences and Informatics
The University of Edinburgh, Medical School
Teviot Place, Edinburgh

Dr Fanny Wai-san Ko
Dept of Medicine and Therapeutics,
The Chinese University of Hong Kong
Shatin, N.T., Hong Kong

Updated January 2019

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations in December of each year using the following definitions:

  • Personal Benefits (Consultancy-Lecture Fees) refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
  • Shares refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
  • Non-Personal Interests refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

View Board and Committee Annual Disclosures